0000000000025399

AUTHOR

Florian Nolte

showing 3 related works from this author

Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.

2017

Myelodysplastic Syndromes are oligo-clonal stem cell disorders that are associated with cytopenias in the peripheral blood. Major causes for morbidity and mortality in myelodysplastic syndromes (MDS) patients are infections mostly due to bacteria or fungi. Beside leucopenia per se in affected patients, function of white blood cells particularly that of neutrophils seems to be impaired. Here we summarize the available data on infections in MDS patients in general and particularly those treated with 5-azacitidine.

medicine.medical_specialtyAntimetabolites AntineoplasticNeutropeniaAzacitidineInfections03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansIn patientMortalityInfection Controlbusiness.industryMyelodysplastic syndromesHematologyGeneral MedicineAntibiotic Prophylaxismedicine.diseasePeripheral blood030220 oncology & carcinogenesisMyelodysplastic SyndromesAzacitidineStem cellMorbiditybusiness030215 immunologymedicine.drugEuropean journal of haematology
researchProduct

Phenotypic and functional characterization of neutrophils and monocytes from patients with myelodysplastic syndrome by flow cytometry.

2016

Myelodysplastic syndrome (MDS) is a clonal stem cell disorder frequently associated with inefficient granulopoiesis showing dysplastic polymorphonuclear neutrophils (PMNs). To assess PMN functionality in MDS in a clinical routine setting, 30 MDS patients and ten healthy volunteers were analyzed for PMN and monocyte phenotype and function (degranulation, CD62L shedding, oxidative burst and phagocytosis) upon stimulation with lipopolysaccharide by multi-color flow cytometry (MCFC). Our data show a heterogeneous pattern for CD66, CD16 and CD64 expression on PMNs of MDS patients. CD62L shedding rate and CD66 degranulation were reduced. Interestingly, we detected correlations between the WHO ada…

0301 basic medicineMaleCell DegranulationNeutrophilsImmunologyCell SeparationBiologyGranulopoiesisCell DegranulationMonocytesFlow cytometryImmunophenotyping03 medical and health sciences0302 clinical medicineMonitoring ImmunologicmedicineHumans610 Medicine & healthAgedMonitoring PhysiologicCD64Aged 80 and overCD11b Antigenmedicine.diagnostic_testMyelodysplastic syndromesMonocyteReceptors IgGDegranulationhemic and immune systemsMiddle Agedmedicine.diseaseFlow CytometryPrognosis030104 developmental biologymedicine.anatomical_structureInternational Prognostic Scoring SystemMyelodysplastic SyndromesImmunologyFemale030215 immunologyCellular immunology
researchProduct

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup …

2016

Abstract Background: Standard therapy of acute promyelocytic leukemia has long relied on the combination of All-trans-retinoic acid (ATRA) and chemotherapy. The introduction of arsenic trioxide (ATO) in APL treatment has allowed achievement of similarly high remission and survival rates coupled with significantly reduced myelosuppression. Recent results of the APL0406 trial by the GIMEMA-AMLSG-SAL study groups showed that the combination of ATRA and arsenic trioxide (ATO) is superior to standard ATRA and chemotherapy (CHT) in front-line therapy of low/intermediate risk acute promyelocytic leukemia (APL). The implications of these results for the clinical practice of APL patients in Germany …

Acute promyelocytic leukemiaChemotherapyPediatricsmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyComplete remissionCell BiologyHematologymedicine.diseaseBiochemistryChemotherapy regimenRegimenchemistry.chemical_compoundchemistryMedicineCumulative incidenceObservational studyArsenic trioxidebusinessneoplasmsBlood
researchProduct